EU Court Revives Ineos Bid For AlphaRen Mark

Law360, New York (February 9, 2011, 6:30 PM EST) -- A European Union court on Wednesday revived Ineos Healthcare Ltd.'s efforts to trademark the name AlphaRen for a new drug, mostly nixing a ruling that backed Teva Pharmaceutical Industries Ltd.'s challenge of the mark.

The EU's General Court found that an appeals board at the Office for Harmonization in the Internal Market erred in rejecting most of Ineos' trademark request based solely on evidence turned up during an Internet search indicating that the company's product was similar to Teva drugs sold under the Alpha D3 mark...
To view the full article, register now.